The Epidemiology of Human Chondrogenic Progenitor Cells

描述（由申请人提供）：该计划旨在通过定义用于选择和优化软骨形成结缔组织祖细胞（CTP-Cs）的可用来源的策略和原则来推进软骨组织工程领域。它还将为组织工程界提供一种严格和标准化的定量方法，用于客观评价和比较细胞来源和处理方案。软骨组织的成功修复或再生需要CTP-Cs的来源，即能够修复或再生软骨组织的天然细胞。 软骨分化。软骨修复策略必须依赖于几种细胞来源之一 战略布局具有软骨形成潜力的CTP存在于软骨以及骨髓、骨膜、肌肉、脂肪和其他组织中。这些组织来源中的几种已经或正在被开发用于提供用于软骨修复和再生程序的细胞。尽管关节软骨组织显示出很少的内在修复能力，但正常和 可以在体外诱导患病软骨组织增殖和分化以表达软骨细胞表型。这种软骨衍生的CTP-C已经成为基于将新鲜分离的软骨组织或培养扩增的细胞移植到软骨缺损中的几种治疗策略的核心。迄今为止，细胞来源决定和细胞加工或制造策略通常不是基于可用细胞来源的浓度、流行率或生物学潜力的定量测定。该计划解决了改善临床实践的三个机会：1）确定成人膝关节（关节软骨，脂肪垫，滑膜，骨膜，软骨下骨和骨髓）中和周围的软骨结缔组织祖细胞（CTP-C）的浓度，患病率和生物学潜力。2)定义软骨组织健康与人类软骨中CTP- Cs的浓度、流行率和生物学潜力之间的关系。3)检验CTP-C源之间的体外性能差异预测体内性能差异的假设。

DESCRIPTION (provided by applicant): This program seeks to advance the field of Cartilage Tissue Engineering by defining strategies and principles for selecting and optimizing available sources of chondrogenic connective tissue progenitors (CTP- Cs). It will also provide the tissue engineering community with a rigorous and standardized quantitative methodology for objective evaluation and comparison of cell sourcing and processing options. Successful repair or regeneration of cartilage tissue requires a source of CTP-Cs, i.e. native cells that are capable of chondrogenic differentiation. Cartilage repair strategies must rely on one of several cell sourcing strategies. CTPs with chondrogenic potential reside in cartilage, as well as bone marrow, periosteum, muscle, fat and other tissues. Several of these tissue sources have already been or are being exploited to provide cells for cartilage repair and regeneration procedures. Although articular cartilage tissue shows little intrinsic capacity to repair, some cells in both normal and diseased cartilage tissue can be induced to proliferate and differentiate to express a chondrocytic phenotype in vitro. Such cartilage-derived CTP-Cs have become central to several treatment strategies based on transplantation of freshly isolated cartilage tissue or culture-expanded cells into a cartilage defect. To date, cell sourcing decisions and cell processing or fabrication strategies have generally not been based on quantitative assays of the concentration, prevalence or biological potential of the available cell sources. This program addresses three opportunities to improve clinical practices: 1) Define the concentration, prevalence and biological potential of chondrogenic connective tissue progenitors (CTP-Cs) in and around the adult human knee (articular cartilage, fat pad, synovium, periosteum, subchondral bone and marrow). 2) Define the relationship between cartilage tissue health and the concentration, prevalence and biological potential of CTP- Cs in human cartilage. 3) Test the hypothesis that differences in in vitro performance between CTP-C sources predict differences in in vivo performance.